Articles tagged with Heart Failure
Researchers at the University of Arizona Health Sciences are studying the molecular mechanisms of coagulation factor XII as a contributor to heart failure with reduced ejection. The goal is to develop better preventive and treatment options for this irreversible condition, which affects millions of Americans.
A significant proportion of American adults suffer from absolute and functional iron deficiency, which can lead to adverse health outcomes. The study highlights the importance of screening strategies for iron deficiency, as it is a common issue that may be overlooked or undertreated.
Researchers identified protein kinase N as a key regulator of heart fibrosis, which threatens heart function. Deleting this enzyme reduced cardiac dysfunction, suggesting anti-PKN treatments may protect against heart failure.
The RESILIENCE clinical trial explores the effectiveness of remote ischemic conditioning to prevent cardiotoxicity in lymphoma patients undergoing anthracycline-based chemotherapy. The trial aims to reduce heart failure prevalence and improve quality of life for cancer survivors.
A recent study published in the New England Journal of Medicine demonstrates the benefits of catheter-based mitral valve repair for patients with moderate to severe mitral regurgitation. The procedure showed a significant reduction in recurrent hospitalisations and improved quality of life after 12 months.
A new study estimates nearly 10.5 million U.S. adults have A-Fib, a three-fold increase from previous estimates. Early detection and treatment can reduce its adverse outcomes.
Research explores relationship between cardiac metabolism dysfunction and heart failure in the elderly, revealing potential therapeutic targets for improved cardiac outcomes. The study highlights the critical role of Pdk4 and MIF in cardiac metabolism, suggesting innovative treatments to manage interconnected cardiovascular conditions.
A study at the European Society of Cardiology Congress found that an AI-enabled digital stethoscope helped doctors identify twice as many cases of pregnancy-related heart failure compared to a control group. The tool was 12 times more likely to flag heart pump weakness, leading to better diagnosis and potentially life-saving treatment.
The FINEARTS-HF trial demonstrates finerenone's benefits in reducing worsening heart failure events and mortality in patients with mildly reduced or preserved ejection fraction. Finerenone significantly reduces total worsening HF events compared to placebo, but shows non-significant reductions in cardiovascular death.
A University of Dundee study has used machine learning to analyze health records of heart failure patients and identify alternative treatment plans that could improve their welfare. The pilot project aims to tailor treatment for each patient, ensuring they receive optimized care with the potential to improve quality of life.
A randomized, placebo-controlled trial found finerenone improved outcomes in patients with heart failure and mildly reduced or preserved ejection fraction. The drug also showed benefits regardless of the ejection fraction and even in patients on other approved therapies.
A randomized controlled trial found that transcatheter edge-to-edge repair (M-TEER) significantly reduced cardiovascular death and hospitalizations for heart failure, compared to medical therapy alone. The study also showed improved health status in patients with moderate to severe functional mitral regurgitation.
Sacubitril/valsartan significantly reduced hospitalization for any reason, particularly in patients with a left ventricular ejection fraction below normal. Lower rates of cardiac and pulmonary hospitalizations were also observed in this patient population.
Researchers at University of California San Diego have identified a novel mechanism of cardiac inflammation that may prevent heart failure after a heart attack. The borderzone, surrounding the infarcted area, is found to be a key region for this inflammation, with heart muscle cells playing a dominant role in initiating it.
A new study found that semaglutide significantly reduces major adverse cardiac events, including heart attacks and strokes, among overweight individuals with cardiovascular disease. The medication also shows similar benefits for people with pre-existing heart failure, regardless of type or severity.
A new risk prediction scale specifically for American Indian adults found elevated heart failure rates compared to other population groups. The analysis identified Type 2 diabetes status, kidney damage, and high blood pressure as major modifiable determinants of developing heart failure over 5-10 years.
Researchers have discovered a new site on beta-2 adrenergic receptors that allows healthy signals to pass through, minimizing harmful side effects of beta-blocker medication. The gut microbial pathway is associated with cardiovascular disease risks and can be independently targeted.
Researchers at the University of Gothenburg found that hearts stored in a 'heart-in-a-box' method experienced lower rates of heart failure and severe organ failure after transplantation. This breakthrough method uses hypothermic oxygenated machine perfusion to keep the heart oxygenated and functioning better.
A new biosensor prototype can measure biomarkers for heart failure in saliva, promising a more accessible and affordable way to screen for the condition. The device, which resembles a COVID-19 test, could enable people with limited access to medical facilities to check on their health regularly.
A new study found that job strain and effort-reward imbalance at work increase the risk of developing atrial fibrillation, an abnormal heart rhythm. The research suggests that recognizing and addressing psychosocial stressors at work can foster healthy environments.
A new heart MRI technique accurately estimates pressures inside the heart to predict heart failure risk in a general population. Key risk factors identified include age over 70, high blood pressure, obesity, alcohol consumption, and male gender.
The American College of Cardiology has released a new guidance on managing patients hospitalized for heart failure, recommending tailored therapy based on clinical trajectory. The updated Expert Consensus Decision Pathway aims to improve disease management and reduce mortality.
New research published in The FASEB Journal shows that blocking CTLA-4 activates Th17 cells, increasing inflammation and damaging the heart. Inhibiting this activation reverses anti-CTLA-4-mediated heart damage.
A UofL cardiologist is leading a Phase II clinical trial of a new stem cell therapy for heart failure, the first in the US to use intravenous delivery. The trial aims to determine whether one or multiple doses of mesenchymal stem cells improve health and quality of life for patients.
Researchers analyzed data from 63,700 patients in five clinical trials to understand the impact of clonal hematopoiesis of indeterminate potential (CHIP) on heart disease. They found that patients with CHIP had a 30% higher risk of initial heart attacks but not recurrent events.
Researchers discovered ultrastructural abnormalities in obese patients with heart failure with preserved ejection fraction (HFpEF), which may be related to the impact of obesity on muscle structure. The study suggests that reducing obesity and using certain medications could help improve HFpEF outcomes.
A new scoring system has been developed to diagnose Heart Failure with Preserved Ejection Fraction (HFpEF), enabling more effective identification of patients. The HFpEF-ABA score model uses age, BMI, and atrial fibrillation to estimate the probability of HFpEF in individual patients.
A recent study published in ESC Heart Failure found that kidney dysfunction can be used as a criterion to stratify patients requiring implantable defibrillators. The research identified two key independent predictors for the risk of sudden cardiac death: left ventricular ejection fraction and estimated glomerular filtration rate.
Researchers found that increasing ketone supply to the hearts of mice with heart failure with preserved ejection fraction (HFpEF) led to improved energy production and pumping ability. This finding suggests a potential new treatment approach for HFpEF, which is a common type of heart failure with no current evidence-based treatment.
Researchers at Tufts University have identified the immune cells driving cardiac inflammation in cancer patients taking doxorubicin, a commonly used chemotherapy drug. Blocking these cells could potentially prevent cardiac damage and make treatment safer for patients.
A new study published in Hypertension journal suggests that both 30-year and 10-year risk predictions should be considered when making high blood pressure treatment decisions. The researchers compared two risk prediction tools and found that long-term, 30-year risk may be more important than short-term, 10-year risk for informing medic...
A study published in Nature Medicine found that off-the-shelf wearable trackers can monitor the response to two treatments for atrial fibrillation and heart failure. The devices provided clinically useful information similar to in-person hospital assessments, with a neural network helping to analyze missing data.
Scientists have identified a critical genetic mechanism driving cardiac fibrosis and found a novel target for its reversal. The discovery sheds light on the role of transforming growth factor-beta (TGFβ) and ATP-citrate lyase (ACLY) in promoting excessive tissue scarring, providing hope for new heart failure treatments.
Researchers found that combining sodium glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists reduces the risk of major adverse cardiovascular events and chronic kidney disease progression by 11% and 33%, respectively. The study suggests using this combination to further improve outcomes in patients with typ...
A new American Heart Association scientific statement highlights the benefits of palliative care in managing symptoms and improving quality of life for people with cardiovascular disease. Palliative care complements standard cardiovascular care by reducing physical symptoms, emotional distress, and assisting patients in making decision...
A recent review of studies on heart failure patients suggests that reducing salt intake has no clinical benefits and may even be counterproductive. Moderate to strict salt restriction was linked with improved quality of life but not mortality or hospitalization rates among patients with heart failure.
The WVU researchers developed a non-invasive, at-home sleep apnea detection device that uses artificial intelligence technology to measure oxygen levels in the blood. Early detection can help prevent worsening of underlying comorbid conditions and reduce healthcare costs, according to Dr. Sunil Sharma.
Researchers found that hospitals that implemented standardized protocols from the American Heart Association and American Stroke Association saw significant reductions in stroke treatment times. The protocols, which include specific limits on time between symptom onset and hospital arrival, helped medical teams respond more quickly to ...
Women with obesity-related heart failure experienced greater weight loss and improved HF symptoms compared to men. Semaglutide improved HF-related symptoms, physical limitations, exercise function, reduced inflammation, and lower blood pressure across both sexes.
Researchers created an integrated cellular map of a mouse model heart, pinpointing cells and pathways involved in fibrosis. The study identified myofibroblasts as the major drivers of scarring, but also discovered a 'matrifibrocyte' form that may prevent scar resolution.
Researchers used a model of the heart and lung system to simulate how microgravity could affect space tourists with underlying health issues, such as heart conditions. The study found that entry into microgravity increases cardiac output in all individuals, but for heart failure patients, this increase is accompanied by a dangerous ris...
Research published in the European Heart Journal found that women diagnosed with perinatal depression are more likely to develop cardiovascular disease. The study included data from around 600,000 women and found a strong link between perinatal depression and risks of high blood pressure, ischemic heart disease, and heart failure.
A study of over 10,000 US adults found a strong association between pro-inflammatory diets and elevated NT-proBNP levels, indicating potential increased cardiovascular risk. The research suggests that dietary inflammatory index may be an important factor in heart failure biomarker levels.
Researchers found a significant association between carpal tunnel syndrome and the risk of developing heart failure and amyloidosis. Individuals with carpal tunnel syndrome were at a 13% higher risk of heart failure and a threefold higher risk of amyloidosis compared to those without the condition.
A study by the University of Michigan Health Frankel Cardiovascular Center found that only 23% of heart attack patients received dietary counseling within 90 days of hospitalization. Nutrition counseling, often provided by registered dietitian nutritionists, may reduce cardiovascular risk for patients.
A mouse study found that heart failure with preserved ejection fraction (HFpEF) differs between male and female mice, with females exhibiting altered heart filament proteins and males showing slowed calcium removal. This may lead to different treatment strategies for women compared to men with HFpEF.
Researchers found that 6% of patients with heart failure progressed to dialysis within a year, highlighting the need for integrating heart and kidney care. The study emphasizes prioritizing kidney function assessment in all patients with heart failure and promoting systemic changes to manage both conditions simultaneously.
A new study reveals that heart failure leaves a 'stress memory' in hematopoietic stem cells, which can lead to recurrent heart failure and other health issues. The researchers propose improving TGF-β levels as a new avenue for treating recurrent heart failure.
The conference will feature 12 late-breaking clinical trials and science presentations on transcatheter aortic valve replacement, mitral and tricuspid devices and techniques. Data from these trials will guide the selection of patients who will benefit most from procedures and define optimal treatment strategies.
Researchers review cell-based therapies for comprehensive sepsis management, highlighting the potential of mesenchymal stem cells and innate immune cells like macrophages. The review also emphasizes the need for further studies on optimal dosage, administration routes, and storage methods to maximize efficacy and safety.
A team of researchers led by Dr. Ahmed discovered that two FDA-approved antibiotics can induce heart regeneration in mammals, showing promise for treating heart failure. The study found that the antibiotics improved cardiac output and reduced fibrotic scar tissue, suggesting a potential new therapy.
A new study has improved the detection of heart failure in women, allowing for earlier diagnosis and potentially life-saving treatment. The research used magnetic resonance imaging to fine-tune how pressures inside the heart are measured, increasing accuracy by 16.5% for female patients.
Researchers found beneficial effects of Sacubitril/Valsartan in reducing inflammation, cardiac fibrosis, and preventing arrhythmias post-MI. The drug has shown promise in mitigating these effects and promoting healthier scar formation.
Cardiovascular biomarkers strongly associated with cardiovascular events and mortality. Adding biomarkers to established risk factors improved heart failure and mortality prediction, but only slightly enhanced atherosclerotic disease risk prediction.
A clinical trial found that aficamten significantly increased maximum oxygen use in patients with obstructive hypertrophic cardiomyopathy. This improvement enables patients to perform everyday tasks more easily, such as walking and household chores. Researchers believe aficamten has promise as a treatment for this condition.
The V142I transthyretin variant is associated with substantial risk for heart failure hospitalization and death in Black individuals, particularly those with reduced ejection fraction. Further investigation into the complex interplay between the variant, ancestry, social determinants of health, and biological factors is warranted.
Researchers studied cardiothoracic surgeons and found that accumulating failures triggers forces both increasing the opportunity to learn and decreasing motivation. This effect is higher for surgeons with lower perceived abilities to learn.
Researchers developed novel glyceraldehyde derivatives from empagliflozin with improved cardiomyocyte protective effects and reduced cytotoxicity. These compounds significantly inhibited NHE1 activity, maintaining intracellular ion homeostasis and exhibiting favorable safety profiles.
A team of researchers at the University of Houston has identified AKAP12 as a promising target for treating heart failure through precision pharmacology. Increased levels of AKAP12 in cardiac myocytes accelerate cardiac dysfunction, but inhibiting PDE8A can reverse this effect and improve contractility.
A new implantable cardiac pump could revolutionize heart transplant care for children, allowing them to wait at home instead of in the hospital. The device performed well in a feasibility trial, with six out of seven children ultimately undergoing transplants and one child's heart recovering on its own.